Roy D. Baynes

Director

Roy D. Baynes (Director) filed 6 Form 4 reports in the trailing twelve months (0 purchases, 6 sales), most often in Travere Therapeutics, Inc. (TVTX). The largest single filing was $2.8M of NTRA (12,780 sh across 8 lots, as filed), executed Nov 19 2025.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

–

no purchases on file

Delay-adjustediThe same average, entered at disclosure dates

–

returns measure stock purchases only

Filings, ttm

0 buys · 6 sells

Median delay

–

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$5.4M

shares × price, as filed

Last traded

Jun 12

Filed Jun 16

Median ADV $454.8M across their filed names

Open performance→

Volume by month

Buys $0 Sells $11.3M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 6 filings

Sector per market data · by filing · past 12 months

Most traded names

TVTX

Travere Therapeutics, Inc. TVTX · 0 buys · 7 sells 7 filings NTRA

Natera, Inc. NTRA · 0 buys · 2 sells 2 filings

Recent filings

TVTXSALE Travere Therapeutics, Inc. View filing → $225K
4,500 sh × $50.00
Exec Jun 12
Filed Jun 16 · 5:30 PM ET TVTXSALE Travere Therapeutics, Inc. View filing → $210K
4,500 sh × $46.65
Exec May 5
Filed May 6 · 5:30 PM ET TVTXSALE Travere Therapeutics, Inc. View filing → $431K
9,750 sh × $44.22
Exec May 1
Filed May 4 · 5:30 PM ET TVTXSALE Travere Therapeutics, Inc. View filing → $1.4M
32,750 sh across 2 lots
Exec Apr 14
Filed Apr 16 · 5:30 PM ET TVTXSALE Travere Therapeutics, Inc. View filing → $330K
10,000 sh × $33.00
Exec Apr 6
Filed Apr 7 · 5:30 PM ET NTRASALE Natera, Inc. View filing → $2.8M
12,780 sh across 8 lots
Exec Nov 19 2025
Filed Nov 21 2025 · 5:30 PM ET TVTXSALE Travere Therapeutics, Inc. View filing → $220K
10,000 sh × $22.00
Exec Feb 6 2025
Filed Feb 10 2025 · 5:30 PM ET TVTXSALE Travere Therapeutics, Inc. View filing → $320K
16,000 sh × $20.00
Exec Jan 23 2025
Filed Jan 23 2025 · 5:30 PM ET More filings →